TG-1 * Transgallaxys Forum 1

Pages: [1]

Author Topic: The partnership makes Lions Club the largest member of the GAVI Matching Fund.  (Read 1869 times)

NoRPthun

  • Jr. Member
  • *
  • Posts: 212

http://www.gavialliance.org sent out this newsletter email:

[*quote*]
GAVI newsletter: Issue 27 - July 2013

Immunisation insights

Lions Club roars about GAVI Matching Fund partnership   
Lions Club International pledges to raise US$ 30 million for immunisation to protect children from measles. This is matched by US$ 30 million from the UK Government and the Bill & Melinda Gates Foundation.

The partnership makes Lions Club the largest member of the GAVI Matching Fund.

DFID: GAVI is a highly effective organisation   
The UK Government's Multilateral Aid Review Update 2013 says that GAVI provides “highly cost-effective health interventions” and “effective financial oversight”.

Alicia Keys and Stevie Wonder headline free concert to support global health   The Global Citizen Festival in New York will kick off a new partnership between the Global Poverty Project and the GAVI Alliance.

 The Festival will take place on 28 September in New York’s Central Park, after the UN General Assembly.

US$ 700 million Vaccine Bond to protect millions of children   
The transaction was the largest by the International Finance Facility for Immunisation since its inaugural 2006 benchmark raised $1 billion. Millions of children in developing countries will benefit from the proceeds that will help fund GAVI programmes.

Polio and other new vaccines - update from GAVI Board   The GAVI Alliance Board has asked the GAVI Secretariat to develop a strategy detailing how GAVI can support the introduction of Inactivated Polio Vaccine in partner countries. The Secretariat will also analyse possible additions to GAVI's vaccine portfolio.

Global vaccine roll-outs: from A to Z   First Angolan child receives pneumococcal vaccine.

Zambian children now protected against two major diseases after introduction of pneumococcal and measles second dose vaccines.

Gender policy public consultation – have your say!   Click here to participate in a survey on gender policy and share your views before 16 August 2013.

 The GAVI gender policy was introduced in 2008 recognising equal access to immunisation as a key factor in ensuring fair coverage.

Immunisation in the newsSave a child this Ramadan
 Majid Al Futtaim Finance, a credit cards cards provider, partners with GAVI

A shot at a healthy future
 by Seth Berkley

Hib vaccine success
 New research on reducing pneumonia and meningitis

The promise of vaccines
 by Siddharth Chatterjee

New vaccine investment strategy
 GAVI is developing a new strategy for the period 2014-2018

GAVI en français"Les Obligations Vaccins (...) peuvent se révéler très rentables et avoir un impact social en sauvant des vies », René Karsenti, Président du Conseil de l’IFFIm

Twitter hashtags
#vaccineswork

#GenderEquality

#MDGmomentum

 Follow us @GAVIAlliance

Copyright © 2013 GAVI Alliance, all rights reserved.
[*/quote*]

Logged

NoRPthun

  • Jr. Member
  • *
  • Posts: 212
Price reduced for vaccine against pneumococcal disease
« Reply #1 on: July 29, 2013, 08:36:04 AM »

http://www.gavialliance.org/library/news/statements/2013/price-reduced-for-vaccine-against-pneumococcal-disease/

[*quote*]
Price reduced for vaccine against pneumococcal disease

New supply agreements reached with manufacturers
 

Copyright GAVI/2007/Atul Loke

Geneva, 29 July 2013 – The price the GAVI Alliance pays for lifesaving pneumococcal vaccines for children in the world’s poorest countries is set to be reduced under new agreements between GAVI, UNICEF, The World Bank, GlaxoSmithKline and Pfizer.

Under previous agreements both manufacturers offered pneumococcal vaccine at US$ 3.50 per dose. From today, Pfizer will provide the vaccine at $3.40 per dose with a further reduction to $3.30 per dose from 2014 onwards. The new prices will apply to all doses to be purchased from Pfizer under current contracts, including those awarded under two previous agreements.

In addition, GSK will lower the price GAVI pays for its pneumococcal vaccine to $3.40 per dose for this new contract covering the period 2014-2024.
Sustainable in the long term

“More than 10 million children have been reached with GAVI-supported pneumococcal vaccines in 29 countries since 2010. We expect to reach children in more than 50 countries with this lifesaving vaccine by 2015,” said Dr Seth Berkley, CEO of the GAVI Alliance. ”We are working hard to make sure all our programmes are sustainable in the long term and one way of doing this is securing the best price we can for vaccines.”
Advance Market Commitment

GAVI purchases pneumococcal vaccines through UNICEF as part of an Advance Market Commitment which aims to accelerate the development of new products, bring forward supply availability and increase the introduction of appropriate and affordable vaccines to tackle pneumococcal disease.

In the past, it has taken up to two decades for vaccines available for children in industrialised countries to reach children in developing countries. Thanks to the innovative AMC, children in GAVI-supported countries have access to pneumococcal vaccines at about the same time as those in high-income countries.

The governments of Italy, the United Kingdom, Canada, the Russian Federation and Norway, and the Bill & Melinda Gates Foundation have committed a total of $1.5 billion to the initiative, which was launched in 2009 and is being implemented by GAVI, The World Bank and UNICEF.
Third GAVI price announcement in 2013

Today’s price reduction is the third to be announced by GAVI this year. In April, a manufacturer agreed to provide pentavalent vaccine for $1.19 per dose. In May, a low price of $4.50 per dose was secured for human papillomavirus (HPV) vaccine.
[*/quote*]
Logged

NoRPthun

  • Jr. Member
  • *
  • Posts: 212
Research shows high impact of Hib vaccines in developing countries
« Reply #2 on: July 29, 2013, 08:38:28 AM »

http://www.gavialliance.org/library/news/statements/2013/research-shows-high-impact-of-hib-vaccines-in-developing-countries/

[*quote*]
Research shows high impact of Hib vaccines in developing countries

Results of Hib Initiative supplement published showing new evidence on the impact of Hib vaccines
 
Clarette Raharimanjaka in Madagascar shows the pentavalent “Easy Five” a GAVI supported vaccine, at Befeletanana Maternity ward in Antananarivo.

25 July 2013 - New evidence carried out by 115 researchers, working in seven different countries over the course of eight years, provides fresh evidence of the impact of Haemophilus influenzae type b (Hib) vaccines on reducing the burden of disease.

Comprising of 13 articles, the research has been published together as the Hib Initiative Supplement in a GAVI sponsored special issue of The Journal of Pediatrics.
Asian and Eastern European countries

With almost all GAVI-eligible countries now using Hib vaccines, as part of the five-in-one pentavalent vaccines, the supplement provides answers to strategic questions that are best addressed following routine usage over time.

The research also provides countries with assurance that Hib vaccines have demonstrated impact, particularly in Asian and Eastern European countries where data was either not available, or interpretation of previous studies was unclear.
Mongolia, Mozambique

In Mongolia, for example, one of the earliest countries in Asia to introduce the Hib vaccine, Hib meningitis incidence decrease from 28 cases per 100,000 children in 2005 to just two per 100,000 by 2010. This contributed to an overall reduction in meningitis incidence, despite increases in other types of meningitis.

And in Mozambique a lasting impact was demonstrated, in spite of high HIV prevalence.
Cost effectiveness of pentavalent vaccine

The supplement also includes a study co-authored by Dr Hope Johnson, formerly at Johns Hopkins Bloomberg School of Public Health but now GAVI’s Head of Programming Outcomes and Impacts, estimating the cost effectiveness of pentavalent vaccine across a variety of scenarios at the state level.

It also demonstrated that the vaccine is highly cost effective, particularly where disease burden is higher and access to care lower.
Eliminated

Prior to widespread vaccine use, Hib was the most common cause of bacterial meningitis and an important cause of severe pneumonia in children under five years old worldwide. Today, thanks in large part to vaccines, the disease has been virtually eliminated in many high-income countries and significantly reduced in low-income countries.

However although Hib conjugate vaccines have been widely used in high-income countries since the 1990s, their uptake has been much slower in developing countries. This is due to multiple barriers, but in particular a lack of local data on disease burden and a lack of awareness of the potential impact of vaccines.
[*/quote*]


To withhold vaccination de facto is child murder. As such it is a crime and must be prosecuted!
Logged
Pages: [1]